For the past 20 years, the standard adjuvant treatment for high-risk resected locally advanced squamous cell carcinoma of the head and neck has been concurrent cisplatin with radiation therapy.[1] The NIVOPOST-OP trial found that the addition of programmed death 1 (PD-1) inhibitor without chemotherapy significantly improved disease-free survival.[1] This combination represents a potential new standard of care in the adjuvant treatment of resected high-risk head and neck cancer.[1] Nivolumab, which is a PD-1 inhibitor, thus becomes a promising alternative to traditional chemotherapy combined with radiation.[1] The results of the study indicate an improvement in the prognosis of patients with this diagnosis.[1]